Moderna-Merck Personalized mRNA Vaccine Linked to Lower Melanoma Recurrence
A new personalized mRNA cancer vaccine, developed by Moderna and Merck, has shown significant success in reducing the recurrence of melanoma tumors by 42% over two years when used alongside standard immunotherapy, according to major study results.
Orlando Daytona Beach Melbourne, FL, October 22, 2026 —
A personalized mRNA cancer vaccine developed by Moderna and Merck was associated with a 42% reduction in melanoma recurrence over two years when used alongside standard immunotherapy, according to study results described in the available summary.
The reported finding concerns the vaccine used in combination with standard immunotherapy. The summary does not provide details about how the study measured recurrence, what group the reduction was compared with, or how many people took part. It also does not identify the study, its publication date, or the researchers who conducted it.
The results are characterized in the summary as showing “significant success,” but no statistical measures or additional findings are included. The information provided does not specify whether the 42% figure represents a relative or absolute reduction, or whether it refers to a particular period within the two-year follow-up.
Other details that could help readers assess the findings—including the vaccine’s name, the study phase, participant characteristics, potential side effects and the length of follow-up beyond two years—were not provided. The summary also does not describe the standard immunotherapy used or indicate whether the results have been published in a scientific journal.
Based on the available information, the reported outcome is limited to reduced melanoma recurrence over two years with the vaccine and immunotherapy combination. Further study details were not included, so the findings cannot be placed in a more specific clinical or research context from this summary alone.
Story summarized from the original created by Lauran Neergaard, Associated Press on www.clickorlando.com, see more information here.
